Inclusion Criteria:

- 5.1.1 Patients must have metastatic or unresectable adenocarcinoma of the pancreas.
The diagnosis of pancreatic adenocarcinoma must be confirmed by histopathology or
cytology.

5.1.2 For the phase I part of this trial, patients who have disease measurable or
evaluable on x-ray, CAT scan, or physical examination are eligible. For the phase II part
of this trial, only patients who have disease measurable on x-ray, CAT scan, or physical
examination are eligible.

5.1.3 Patients must have no history of prior chemotherapy. 5.1.4 Patients with prior
radiotherapy are eligible if the irradiated area is not the only source of measurable or
evaluable disease.

5.1.5 Patients’ baseline ECOG performance status must be £ 2. 5.1.6 Patients’ life
expectancy must be 12 weeks or greater. 5.1.7 Patients’ age must be ³ 20 and £ 75. 5.1.8
Patients must have adequate bone marrow function, defined as WBC count ³ 3,500/ul,
neutrophil count ³ 1,500/ul, and platelet count ³ 100,000/ul.

5.1.9 Patients must have adequate liver function and adequate renal function, defined as
the following: serum alanine (ALT) £ 5 times upper normal limit, serum total bilirubin
level £ 2.0 mg/dL, and serum creatinine £ 1.5 mg/dL.

5.1.10 Patients who have biliary obstruction and have undergone adequate drainage
procedures before enrollment are eligible.

5.1.11 Patients must agree to have indwelling venous catheter implanted. 5.1.12 Women or
men of reproductive potential may not participate unless they have agreed to use an
effective contraceptive method.

5.1.13 All patients must be informed of the investigational nature of this study and must
sign and give written informed consent.

Exclusion Criteria:5.2.1 Patients who have central nervous system metastasis 5.2.2
Patients who have active infection 5.2.3 Pregnant or breast-nursing women 5.2.4 Patients
who have active cardiac disease or history of ischemic heart disease 5.2.5 Patients who
have peripheral neuropathy > Grade I of any etiology 5.2.6 Patients who have serious
concomitant systemic disorders incompatible with the study (at the discretion of the
investigator) 5.2.7 Patients who have other prior or concurrent malignancy except for
adequately treated in situ carcinoma of cervix or adequately treated basal cell carcinoma
of skin 5.2.8 Patients who are under biologic treatment for their malignancy

-